126 related articles for article (PubMed ID: 37418000)
1. Re-evaluation and a Structure-Activity Relationship Study for the Selective Anti-anaerobic Bacterial Activity of Luminamicin toward Target Identification.
Kimishima A; Negami S; Tsuruoka I; Tsutsumi H; Matsui H; Sugamata M; Kondo N; Honsho M; Sakai K; Honma S; Naher K; Watanabe Y; Iwatsuki M; Inahashi Y; Hanaki H; Asami Y
ACS Infect Dis; 2023 Aug; 9(8):1602-1609. PubMed ID: 37418000
[TBL] [Abstract][Full Text] [Related]
2. Chemical Degradation-Inspired Total Synthesis of the Antibiotic Macrodiolide, Luminamicin.
Kimishima A; Ando H; Sennari G; Noguchi Y; Sekikawa S; Kojima T; Ohara M; Watanabe Y; Inahashi Y; Takada H; Sugawara A; Matsumaru T; Iwatsuki M; Hirose T; Sunazuka T
J Am Chem Soc; 2022 Dec; 144(50):23148-23157. PubMed ID: 36487183
[TBL] [Abstract][Full Text] [Related]
3. Stereostructure of luminamicin, an anaerobic antibiotic, via molecular dynamics, NMR spectroscopy, and the modified Mosher method.
Gouda H; Sunazuka T; Ui H; Handa M; Sakoh Y; Iwai Y; Hirono S; Omura S
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18286-91. PubMed ID: 16344486
[TBL] [Abstract][Full Text] [Related]
4. [Antimicrobial profile and clinical evidence of fidaxomicin (Dafclir
Takeda S; Miki T
Nihon Yakurigaku Zasshi; 2019; 154(4):217-229. PubMed ID: 31597902
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
6.
Oka D; Yamaya N; Kuno T; Asakawa Y; Shiragiku T; Chen L; Xue J; Mamuti A; Ye F; Sun J; Ohguro K; Miyamoto H; Uematsu Y; Inagaki K; Cheng JF; Matsumoto M
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495229
[TBL] [Abstract][Full Text] [Related]
7. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
8. Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis.
Brauer M; Herrmann J; Zühlke D; Müller R; Riedel K; Sievers S
Gut Pathog; 2022 Jan; 14(1):4. PubMed ID: 34991700
[TBL] [Abstract][Full Text] [Related]
9. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile.
Murray B; Wolfe C; Marra A; Pillar C; Shinabarger D
J Antimicrob Chemother; 2020 Aug; 75(8):2149-2155. PubMed ID: 32285102
[TBL] [Abstract][Full Text] [Related]
11. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
[TBL] [Abstract][Full Text] [Related]
12. Nitro-Group-Containing Thiopeptide Derivatives as Promising Agents to Target
Kim D; Kim YR; Hwang HJ; Ciufolini MA; Lee J; Lee H; Clovis S; Jung S; Oh SH; Son YJ; Kwak JH
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631450
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T; Huesgen E; Danziger L
Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
15. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
16. Novel fidaxomicin antibiotics through site-selective catalysis.
Dailler D; Dorst A; Schäfle D; Sander P; Gademann K
Commun Chem; 2021 May; 4(1):59. PubMed ID: 36697765
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin Use in the Pediatric Population with
Oliver MB; Vaughn BP
Clin Pharmacol; 2022; 14():91-98. PubMed ID: 36177387
[No Abstract] [Full Text] [Related]
18. [Clostridioides difficile: updated recommendations].
Barbut F; Eckert C; Lalande V; Le Neindre K; Couturier J
Rev Prat; 2022 Sep; 72(7):703-709. PubMed ID: 36511953
[TBL] [Abstract][Full Text] [Related]
19. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores.
Bassères E; Endres BT; Montes-Bravo N; Pérez-Soto N; Rashid T; Lancaster C; Begum K; Alam MJ; Paredes-Sabja D; Garey KW
Anaerobe; 2021 Jun; 69():102352. PubMed ID: 33640461
[TBL] [Abstract][Full Text] [Related]
20. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
